ERBB2 and neoplasm: We successfully armed innate-like NKp30+CD8+ T cells with tumor-reactive TCRs or CARs targeting HER2, thus endowing this CD8+ T cell population with dual-recognition potential against tumors, both in an MHC/antigen-dependent and independent manner.